Literature DB >> 22814393

Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes.

Antonio Julià1, Raül Tortosa, José Manuel Hernanz, Juan D Cañete, Eduardo Fonseca, Carlos Ferrándiz, Pablo Unamuno, Lluís Puig, José Luís Fernández-Sueiro, Raimon Sanmartí, Jesús Rodríguez, Jordi Gratacós, Esteban Dauden, José Luís Sánchez-Carazo, José Luís López-Estebaranz, David Moreno-Ramírez, Rubén Queiró, Carlos Montilla, Juan Carlos Torre-Alonso, José Javier Pérez-Venegas, Francisco Vanaclocha, Enrique Herrera, Santiago Muñoz-Fernández, Carlos González, Daniel Roig, Alba Erra, Isabel Acosta, Antonio Fernández-Nebro, Pedro Zarco, Arnald Alonso, María López-Lasanta, Andrés García-Montero, Josep Lluís Gelpí, Devin Absher, Sara Marsal.   

Abstract

Recent genome-wide association studies (GWASs) have identified >20 new loci associated with the susceptibility to psoriasis vulgaris (PsV) risk. We investigated the association of PsV and its main clinical subphenotypes with 32 loci having previous genome-wide evidence of association with PsV (P < 5e-8) or strong GWAS evidence (P < 5e-5 in discovery and P < 0.05 in replication sample) in a large cohort of PsV patients (n = 2005) and controls (n = 1497). We provide the first independent replication for COG6 (P = 0.00079) and SERPINB8 (P = 0.048) loci with PsV. In those patients having developed psoriatic arthritis (n = 955), we found, for the first time, a strong association with IFIH1 (P = 0.013). Analyses of clinically relevant PsV subtypes yielded a significant association of severity of cutaneous disease with variation at LCE3D locus (P = 0.0005) in PsV and nail involvement with IL1RN in purely cutaneous psoriasis (PsC, P = 0.007). In an exploratory analysis of epistasis, we replicated the previously described HLA-C-ERAP1 interaction with PsC. Our findings show that common genetic variants associated with a complex phenotype like PsV influence different subphenotypes of high clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814393     DOI: 10.1093/hmg/dds295

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

Review 1.  [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].

Authors:  C Günther; F Schmidt; N König; M A Lee-Kirsch
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

2.  Association with Genetic Variants in the IL-23 and NF-κB Pathways Discriminates between Mild and Severe Psoriasis Skin Disease.

Authors:  Pernilla Nikamo; Josefin Lysell; Mona Ståhle
Journal:  J Invest Dermatol       Date:  2015-03-19       Impact factor: 8.551

3.  Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis.

Authors:  A Julià; C Ferrándiz; E Dauden; E Fonseca; E Fernández-López; J L Sanchez-Carazo; F Vanaclocha; L Puig; D Moreno-Ramírez; J L Lopez-Estebaranz; E Herrera; P de la Cueva; G Ávila; A Alonso; R Tortosa; M López-Lasanta; S Marsal
Journal:  Pharmacogenomics J       Date:  2014-11-18       Impact factor: 3.550

4.  Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.

Authors:  Philip E Stuart; Rajan P Nair; Lam C Tsoi; Trilokraj Tejasvi; Sayantan Das; Hyun Min Kang; Eva Ellinghaus; Vinod Chandran; Kristina Callis-Duffin; Robert Ike; Yanming Li; Xiaoquan Wen; Charlotta Enerbäck; Johann E Gudjonsson; Sulev Kõks; Külli Kingo; Tõnu Esko; Ulrich Mrowietz; Andre Reis; H Erich Wichmann; Christian Gieger; Per Hoffmann; Markus M Nöthen; Juliane Winkelmann; Manfred Kunz; Elvia G Moreta; Philip J Mease; Christopher T Ritchlin; Anne M Bowcock; Gerald G Krueger; Henry W Lim; Stephan Weidinger; Michael Weichenthal; John J Voorhees; Proton Rahman; Peter K Gregersen; Andre Franke; Dafna D Gladman; Gonçalo R Abecasis; James T Elder
Journal:  Am J Hum Genet       Date:  2015-11-28       Impact factor: 11.025

Review 5.  The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.

Authors:  Marina Talamonti; Simone D'Adamio; Luca Bianchi; Marco Galluzzo
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

6.  A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.

Authors:  Sofia Masouri; Irene Stefanaki; Giorgos Ntritsos; Katerina P Kypreou; Eleni Drakaki; Evangelos Evangelou; Electra Nicolaidou; Alexandros John Stratigos; Christina Antoniou
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

7.  Mouse model of imiquimod-induced psoriatic itch.

Authors:  Kent Sakai; Kristen M Sanders; Marina R Youssef; Kevin M Yanushefski; Liselotte Jensen; Gil Yosipovitch; Tasuku Akiyama
Journal:  Pain       Date:  2016-11       Impact factor: 7.926

8.  Common variants of ZNF750, RPTOR and TRAF3IP2 genes and psoriasis risk.

Authors:  T Dębniak; E Soczawa; M Boer; M Różewicka-Czabańska; J Wiśniewska; P Serrano-Fernandez; A Mirecka; K Paszkowska-Szczur; J Lubinski; L Krysztoforska; Z Adamski; R Maleszka
Journal:  Arch Dermatol Res       Date:  2013-09-05       Impact factor: 3.017

Review 9.  Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review.

Authors:  Michelle L M Mulder; Tamara W van Hal; Mark H Wenink; Hans J P M Koenen; Frank H J van den Hoogen; Elke M G J de Jong; Juul M P A van den Reek; Johanna E Vriezekolk
Journal:  Arthritis Res Ther       Date:  2021-06-14       Impact factor: 5.156

Review 10.  Genetics of psoriasis and pharmacogenetics of biological drugs.

Authors:  Rocío Prieto-Pérez; Teresa Cabaleiro; Esteban Daudén; Dolores Ochoa; Manuel Roman; Francisco Abad-Santos
Journal:  Autoimmune Dis       Date:  2013-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.